Refine
Year of publication
- 2021 (1)
Document Type
- Article (1)
Language
- English (1)
Has Fulltext
- yes (1)
Is part of the Bibliography
- no (1)
Keywords
- Alternative splicing (1)
- Blinatumomab (1)
- CD19 (1)
- Exitrons (1)
- Immunotherapy (1)
- Long-read sequencing (1)
- Oxford Nanopore Technologies (1)
- Reverse transcription (1)
- mRNA isoforms (1)
Institute
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (1) (remove)
Resistance to CD19-directed immunotherapies in lymphoblastic leukemia has been attributed, among other factors, to several aberrant CD19 pre-mRNA splicing events, including recently reported excision of a cryptic intron embedded within CD19 exon 2. While “exitrons” are known to exist in hundreds of human transcripts, we discovered, using reporter assays and direct long-read RNA sequencing (dRNA-seq), that the CD19 exitron is an artifact of reverse transcription. Extending our analysis to publicly available datasets, we identified dozens of questionable exitrons, dubbed “falsitrons,” that appear only in cDNA-seq, but never in dRNA-seq. Our results highlight the importance of dRNA-seq for transcript isoform validation.